Navigation Links
Cedarburg Hauser Granted DEA Registration for Denver Manufacturing Facility
Date:2/27/2013

DENVER, Feb. 27, 2013 /PRNewswire/ -- Cedarburg Hauser Pharmaceuticals (CHP), a contract development and manufacturing organization (CDMO), announced today that its Denver, Colorado facility has been granted registration as a manufacturer of schedule II-V controlled substances by the U.S Drug Enforcement Agency (DEA).

The new DEA registration status is the result of a concerted effort to enhance infrastructure and adopt procedural controls that facilitate compliance with DEA requirements. The ability to manufacture controlled substances affords the company additional capacity when added to the pre-existing controlled substance manufacturing capabilities at its Grafton, Wisconsin facility.

"The GMP manufacturing and analytical method development expertise of Cedarburg Hauser's Denver facility may now be extended to DEA scheduled compounds," says Vice President and General Manager, Joe Guiles . "This further emphasizes these competencies, and represents an opportunity to expand our customer base and serve the needs of our existing customers."

"The development and manufacturing of controlled substances requires stringent controls and security measures," added Dan Childers , VP of Quality Assurance and Regulatory Compliance. "DEA registration further illustrates the strength of the manufacturing, handling and storage controls in place at Cedarburg Hauser's Denver facility."

The registration is filed under InB: Hauser Pharmaceutical Services, and allows for the immediate manufacture of schedule II-V compounds.

About Cedarburg Hauser Pharmaceuticals

Cedarburg Hauser Pharmaceuticals is an experienced, contract development and manufacturing organization (CDMO), specializing in small molecule active pharmaceutical ingredients (API) and pharmaceutical intermediates. Cedarburg Hauser leverages a talented group of scientists and supporting -staff, as well as a centralized approach to project management, to ensure on-time and on-budget completion of projects involving the development, scale-up, and manufacturing of complex APIs.

Media Contact:

Bob Forner , Marketing Manager  
Cedarburg Hauser Pharmaceuticals
P: 262-376-1670 x 117
Email: bob.forner@cedarburghauser.com   
www.cedarburghauser.com

This press release was issued through eReleases® Press Release Distribution. For more information, visit http://www.ereleases.com.


'/>"/>
SOURCE Cedarburg Hauser
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Inovio Pharmaceuticals Granted U.S. Patent Protection for Synthetic Vaccine for Cervical Dysplasia and Cancer
2. Broad Patent Protection Granted for iBio Immunomodulator
3. BiO2 Medical Granted CE Mark for the Angel™ Catheter, the First IVC Filter with a Prophylactic Use Indication
4. QRxPharma Granted Additional US Patent on MoxDuo®
5. Oramed Pharmaceuticals Granted Core Technology Patent in New Zealand
6. Unilife Granted Key U.S. Patent for Unifill Prefilled Syringe
7. Vomaris patent estate grows to six issued U.S. patents and three granted international patents with U.S. Pat. No. 8,224,439
8. OncoSec Granted New Patent from China
9. Albireo Has Been Granted Orphan Drug Designation for A4250 from the US FDA for the Treatment of Progressive Familial Intrahepatic Cholestasis (PFIC) and for Primary Biliary Cirrhosis (PBC)
10. Savara Pharmaceuticals AeroVanc Granted U.S. Orphan Drug Designation for the Treatment of MRSA Lung Infection in Cystic Fibrosis Patients
11. Harvest Technologies Corporation Granted CE Mark for Expanded Clinical Indication for Treatment of No-Option Critical Limb Ischemia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... INDIANAPOLIS , June 23, 2016 Roche ... received 510(k) clearance for its Elecsys BRAHMS PCT (procalcitonin) ... severe sepsis or septic shock. With this clearance, Roche ... provide a fully integrated solution for sepsis risk assessment ... associated with bacterial infection and PCT levels in blood ...
(Date:6/23/2016)... June 23, 2016 Research and Markets ... Issue 52" report to their offering. ... treatment creates a favourable commercial environment for MedImmune to enter. ... base that will serve to drive considerable growth for effective ... serve to cap sales considerably, but development is still in ...
(Date:6/23/2016)... INDIANAPOLIS , June 23, 2016 ... Tomorrow,s Leaders Scholarship is any indication, the future is ... online at www.diabetesscholars.org by the Diabetes Scholars ... in the way of academic and community service excellence. ... program since 2012, and continues to advocate for people ...
Breaking Medicine Technology:
(Date:6/25/2016)... , ... June 25, 2016 , ... ... and non-athletes recover from injury. Recently, he has implemented orthobiologic procedures as a ... area —Johnson is one of the first doctors to perform the treatment. Orthobiologics ...
(Date:6/25/2016)... ... , ... Conventional wisdom preaches the benefits of moderation, whether it’s a matter ... bar too high can result in disappointment, perhaps even self-loathing. However, those who set ... , Research from PsychTests.com reveals that behind the tendency to set low ...
(Date:6/24/2016)... ... , ... Those who have experienced traumatic events may suffer from a complex ... as drug or alcohol abuse, as a coping mechanism. To avoid this pain and ... a traumatic event. , Trauma sufferers tend to feel a range of emotions, from ...
(Date:6/24/2016)... ... June 24, 2016 , ... Marcy was in a crisis. Her son James, eight, was ... his family verbally and physically. , “When something upset him, he couldn’t control his emotions,” ... He would throw rocks at my other children and say he was going to kill ...
(Date:6/24/2016)... Fla. (PRWEB) , ... June 24, 2016 , ... Global ... Trend magazine’s 2016 Legal Elite. The attorneys chosen by their peers for this recognition ... Florida. , Seven Greenberg Traurig Shareholders received special honors as members of this year’s ...
Breaking Medicine News(10 mins):